2020
Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder
D’Souza D, Radhakrishnan R, Naganawa M, Ganesh S, Nabulsi N, Najafzadeh S, Ropchan J, Ranganathan M, Cortes-Briones J, Huang Y, Carson RE, Skosnik P. Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. Molecular Psychiatry 2020, 26: 3192-3200. PMID: 32973170, DOI: 10.1038/s41380-020-00891-4.Peer-Reviewed Original ResearchConceptsHippocampal synaptic densityCannabis use disorderHealthy controlsSynaptic densityPositron emission tomographyUse disordersDSM-5 cannabis use disorderVivo evidenceAdministration of cannabinoidsHippocampal synaptic integrityVerbal memory taskSynaptic vesicle glycoprotein 2AHuman cannabis usersEffects of cannabisWarrants further studyPlasma input functionMemory taskCentrum semiovaleAdult rodentsOne-tissue compartment modelSynaptic integrityHippocampal functionCannabis misuseArterial samplingEmission tomography
2018
Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans
Skosnik PD, Hajós M, Cortes-Briones JA, Edwards CR, Pittman BP, Hoffmann WE, Sewell AR, D'Souza DC, Ranganathan M. Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans. Neuropharmacology 2018, 135: 412-423. PMID: 29604295, PMCID: PMC6091633, DOI: 10.1016/j.neuropharm.2018.03.036.Peer-Reviewed Original ResearchConceptsLocal field potentialsSensory gatingCP 55940AM 251Dual-click paradigmNeural oscillationsCannabinoid receptor 1P50 gating ratioGating ratioCannabinoid administrationCB1R agonistEndocannabinoid systemOutcome measuresTranslational studiesReceptor 1Brain regionsAnimal dataCannabis useRatsCannabidiolPlaceboTHC conditionsField potentialsTest dayHuman subjects
2014
Testing differences in the activity of event-related potential sources: Important implications for clinical researchers
Cortes-Briones JA, Cahill JD, Ranganathan M, Sewell RA, D’Souza D, Skosnik PD. Testing differences in the activity of event-related potential sources: Important implications for clinical researchers. Clinical Neurophysiology 2014, 126: 215-218. PMID: 24840905, DOI: 10.1016/j.clinph.2014.04.008.Peer-Reviewed Original Research
2013
Spicing things up: synthetic cannabinoids
Spaderna M, Addy PH, D’Souza D. Spicing things up: synthetic cannabinoids. Psychopharmacology 2013, 228: 525-540. PMID: 23836028, PMCID: PMC3799955, DOI: 10.1007/s00213-013-3188-4.Peer-Reviewed Original Research
2010
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal JH, Mathew SJ, D’Souza D, Garakani A, Gunduz-Bruce H, Charney DS. Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs 2010, 24: 669-693. PMID: 20658799, DOI: 10.2165/11533230-000000000-00000.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPreliminary clinical trialsPositive allosteric modulatorsPsychiatric disordersClinical trialsAnimal modelsAllosteric modulatorsGroup II mGluR agonistGroup IMetabotropic glutamate receptor agonistAnxiety disordersPotential psychiatric applicationsGlutamate receptor agonistsMetabotropic glutamate receptorsTreatment of schizophreniaRole of glutamateForm of depressionMGluR agonistAntidepressant propertiesMGluR5 agonistReceptor agonistGlutamate receptorsMood disordersArea of schizophreniaPromising agentAgonists
2009
Modelling psychosis
Curran HV, D’Souza D, Robbins TW, Fletcher P. Modelling psychosis. Psychopharmacology 2009, 206: 513-514. PMID: 19756521, DOI: 10.1007/s00213-009-1663-8.Peer-Reviewed Original ResearchNeuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia
Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today 2009, 14: 690-697. PMID: 19460458, PMCID: PMC2898127, DOI: 10.1016/j.drudis.2009.05.002.Peer-Reviewed Original ResearchConceptsPsychiatric disordersSymptomatic reliefMood disordersAnxiety disordersNeuroplasticity deficitsCurrent pharmacotherapyUnderlying abnormalityCurrent treatmentPsychiatric treatmentNeuroplasticityDisordersPharmacotherapyTreatmentExciting new findingsSchizophreniaReliefAbnormalitiesNeurodevelopmentNew findingsPreventionCannabinoids and psychosis
Sewell RA, Ranganathan M, D'Souza DC. Cannabinoids and psychosis. International Review Of Psychiatry 2009, 21: 152-162. PMID: 19367509, DOI: 10.1080/09540260902782802.Peer-Reviewed Original ResearchConceptsGeneral populationPsychotic disordersTrigger relapseCannabis usersCognitive symptomsCross-sectional studyIndividual vulnerabilityCannabis useCannabinoid receptor functionLongitudinal studyCase seriesPsychotic illnessPsychotic symptomsCannabisHealthy individualsSchizophreniaPharmacological studiesReceptor functionAutobiographical accountsPsychosisEarly exposureSymptomsTwo-fold increaseConsiderable evidenceComponent causes
2007
Cannabinoids and Psychosis
D'Souza DC. Cannabinoids and Psychosis. International Review Of Neurobiology 2007, 78: 289-326. PMID: 17349865, DOI: 10.1016/s0074-7742(06)78010-2.Peer-Reviewed Original ResearchConceptsReceptor dysfunctionPsychotic disordersTransient psychotic symptomsRecent epidemiological studiesComponent causesRates of cannabisRates of schizophreniaCauses of schizophreniaWarrants further studyAcute psychosisLung cancerCannabis exposureCannabinoid functionHigh riskPsychotic symptomsEpidemiological studiesPeriod of intoxicationPsychosisAvailable evidenceSchizophreniaCannabinoidsGenetic riskBiological plausibilityFurther studiesDysfunction
2006
The acute effects of cannabinoids on memory in humans: a review
Ranganathan M, D’Souza D. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology 2006, 188: 425-444. PMID: 17019571, DOI: 10.1007/s00213-006-0508-y.Peer-Reviewed Original ResearchConceptsStages of memoryHuman literatureDelay-dependent mannerIntrusion errorsMemory taskFree recallPsychological testsAmnestic effectsCognitive functionConstituent cannabinoidsRobust effectMemoryPreclinical literatureFuture researchResultsAcute administrationNeurochemical basisEffects of cannabinoidsDrug useExogenous cannabinoidsIssues of doseAcute effectsLarge bodyLong-term potentiationSmall sample sizeRationaleCannabis
2003
NMDA Receptor Antagonism and the Ethanol Intoxication Signal
KRYSTAL JH, PETRAKIS IL, KRUPITSKY E, SCHÜTZ C, TREVISAN L, D'SOUZA DC. NMDA Receptor Antagonism and the Ethanol Intoxication Signal. Annals Of The New York Academy Of Sciences 2003, 1003: 176-184. PMID: 14684445, DOI: 10.1196/annals.1300.010.Peer-Reviewed Original ResearchNMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development
Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 2003, 169: 215-233. PMID: 12955285, DOI: 10.1007/s00213-003-1582-z.Peer-Reviewed Original ResearchConceptsTreatment of schizophreniaReceptor antagonistN-methyl-D-aspartate (NMDA) glutamate receptor antagonistPharmacotherapy of schizophreniaGlutamate receptor antagonistsReceptor antagonist effectsNMDA receptor antagonistNMDA receptor antagonist effectsNMDA receptor contributionTranslational Neuroscience ApproachGlutamatergic activityGlutamatergic functionNew medicationsClinical studiesReceptor contributionTherapeutic implicationsMedication developmentCortical connectivityAntagonist effectsAntagonist responseNew treatment insightsSchizophreniaModel psychosisTreatment insightsAntagonistN-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability
Krystal JH, Petrakis IL, Mason G, Trevisan L, D'Souza DC. N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacology & Therapeutics 2003, 99: 79-94. PMID: 12804700, DOI: 10.1016/s0163-7258(03)00054-8.Peer-Reviewed Original ResearchConceptsGlutamatergic systemEthanol abuseGlutamate receptorsN-methyl-D-aspartate (NMDA) subtypePrimary excitatory neurotransmitterAspartate glutamate receptorsAction of ethanolEthanol withdrawalGlutamatergic agentsGlutamatergic functionExcitatory neurotransmitterTranslational neuroscience perspectiveGlutamate systemEthanol intoxicationBehavioral effectsEthanol contributeAlcoholismBrainReceptorsTreatmentAbuseN-methylSubtypesNeurotransmittersIntoxication
1997
Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans
Laruelle M, D’Souza C, Baldwin R, Abi-Dargham A, Kanes S, Fingado C, Seibyl J, Zoghbi S, Bowers M, Jatlow P, Charney D, Innis R. Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans. Neuropsychopharmacology 1997, 17: 162-174. PMID: 9272483, DOI: 10.1016/s0893-133x(97)00043-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAffectAlpha-MethyltyrosineAnimalsBenzamidesBrainDopamineEnzyme InhibitorsHomovanillic AcidHumansIodine RadioisotopesMaleMethoxyhydroxyphenylglycolParkinson Disease, SecondaryPyrrolidinesRatsRats, Sprague-DawleyReceptors, Dopamine D2Tomography, Emission-Computed, Single-PhotonTyrosine 3-MonooxygenaseConceptsAcute dopamine depletionSynaptic dopamine concentrationsEndogenous dopamineDopamine depletionPositron emission tomographyD2 receptorsTyrosine hydroxylase inhibitor alpha-methylDopamine concentrationsD2 receptor imagingD2 receptor upregulationD2 receptor occupancySingle photon emissionPara-tyrosineReceptor upregulationReceptor imagingAlpha-methylReceptor occupancyEmission tomographyDopaminePhoton emissionHuman brainReceptorsTomographyRodentsVivo measurements
1996
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.
Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings Of The National Academy Of Sciences Of The United States Of America 1996, 93: 9235-9240. PMID: 8799184, PMCID: PMC38625, DOI: 10.1073/pnas.93.17.9235.Peer-Reviewed Original ResearchConceptsAmphetamine-induced dopamine releaseDopamine releaseDopaminergic transmissionPsychotic symptomsSchizophrenic groupDopamine D2 receptor availabilityAmphetamine-induced decreaseAmphetamine-induced reductionD2 receptor availabilityD2 receptor radiotracerPositive psychotic symptomsSingle photon emissionExaggerated stimulationAbnormal responsivenessDopaminergic neuronsHealthy controlsReceptor radiotracerSchizophrenic patientsDopamine hypothesisDopamine functionReceptor availabilityAmphetamine effectsControl groupSchizophrenic subjectsSchizophrenia